Compare FUND & ARCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FUND | ARCT |
|---|---|---|
| Founded | 1988 | 2013 |
| Country | Canada | United States |
| Employees | N/A | 176 |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 291.7M | 224.8M |
| IPO Year | N/A | 2019 |
| Metric | FUND | ARCT |
|---|---|---|
| Price | $10.04 | $7.65 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $38.44 |
| AVG Volume (30 Days) | 33.5K | ★ 401.4K |
| Earning Date | 01-01-0001 | 06-08-2026 |
| Dividend Yield | ★ 6.64% | N/A |
| EPS Growth | N/A | ★ 20.00 |
| EPS | ★ 0.93 | N/A |
| Revenue | N/A | ★ $82,031,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $10.67 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.21 | $5.85 |
| 52 Week High | $10.16 | $24.14 |
| Indicator | FUND | ARCT |
|---|---|---|
| Relative Strength Index (RSI) | 62.95 | 49.83 |
| Support Level | $8.08 | $7.00 |
| Resistance Level | N/A | $7.88 |
| Average True Range (ATR) | 0.16 | 0.51 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 76.72 | 48.39 |
Sprott Focus Trust Inc is a diversified closed-end investment company. Its primary investment objective is long-term capital growth. To achieve its objective, The Fund may invest its assets in equity securities and in direct obligations of the U.S. Government or its agencies and in the non-convertible preferred stocks & debt securities of domestic and foreign companies. It invests in various sectors, of which Materials, Financials, Energy, Information technology sector account for the majority weightage.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. It operates in one business segment, which includes all activities related to the discovery, development, and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC and LUNAR-CF. Its Vaccine candidates include LUNAR-FLU, KOSTAIVE XBB.1.5, KOSTAIVE, and Others.